Alemtuzumab in B-cell chronic lymphocytic leukemia

Clin Lymphoma. 2004 Mar;4(4):228-9. doi: 10.1016/s1526-9655(11)70038-0.
No abstract available

Publication types

  • Review
  • Comment

MeSH terms

  • Aged
  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Antigens, CD / immunology
  • Antigens, Neoplasm / immunology
  • Antineoplastic Agents / therapeutic use*
  • CD52 Antigen
  • Disease Progression
  • Glycoproteins / immunology
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Middle Aged
  • Prognosis
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antigens, CD
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • CD52 Antigen
  • CD52 protein, human
  • Glycoproteins
  • Alemtuzumab